Proteomics

Dataset Information

0

Effect of SMARCA2/SMARCA4 inhibitor, FHD-286, on protein expression alterations in cultured cell line or patient-derived AML cells with MECOM rearrangement and expression of EVI1

ABSTRACT: Cultured cell line UCSD-AML1 (45,XX,-7,t(3;3)(q21;q26)) and patient-derived AML194 (acute myeloid leukemia with inv3(q21;q26.2)) cells were treated in duplicate with 0 nM or 100 nM of FHD-286 for 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with a small molecule, chromatin remodeling complex protein, dual SMARCA2/SMARCA4 enzymatic activity inhibitor in MECOM rearranged AML cells with EVI1 overexpression. We also compared the global expression changes that were common between the two FHD-286-treated AML subtypes.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Antrix Jain  

LAB HEAD: Kapil Bhalla

PROVIDER: PXD059060 | Pride | 2026-01-23

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
53219_1_ECL_1068_hs_TMT10_MS2_plex2_prof_250ng_F01.pepXML Pepxml
53219_1_ECL_1068_hs_TMT10_MS2_plex2_prof_250ng_F01.raw Raw
53219_1_ECL_1068_hs_TMT10_MS2_plex2_prof_250ng_F02.pepXML Pepxml
53219_1_ECL_1068_hs_TMT10_MS2_plex2_prof_250ng_F02.raw Raw
53219_1_ECL_1068_hs_TMT10_MS2_plex2_prof_250ng_F03.pepXML Pepxml
Items per page:
1 - 5 of 50
altmetric image

Publications

In AML with 3q26.2 rearrangements (r) the distal GATA2 hematopoietic enhancer becomes aberrantly relocated leading to activation of EVI1 expression. EVI1 is a transcriptional regulator that plays a role in proliferation and maintenance of a stem cell-like phenotype in AML. BRG1 (SMARCA4) and BRM (SMARCA2) are the mutually exclusive ATPases of the BAF (BRG1/BRM-associated factor) chromatin remodeling complexes. They regulate access to enhancers/promoters and gene-expressions orchestrating AML ste  ...[more]

Similar Datasets

Proteomics Effect of SMARCA2/SMARCA4 inhibitor, FHD-286, on protein expression alterations in cultured cell line or patient-derived AML cells with MECOM rearrangement and expression of EVI1
2026-01-23 | PXD059059 | Pride
Proteomics Determination of protein expression changes due to treatment with chromatin remodeling inhibitor FHD-286 in patient-derived mutant NPM1 and FLT-ITD-expressing AML cells
2025-05-06 | PXD047967 | Pride
Proteomics Determination of protein expression changes due to treatment with chromatin remodeling inhibitor FHD-286 in MLL1-rearranged AML cells
2025-05-26 | PXD047965 | Pride
Proteomics Project title: Effect of FHD-286 or BRG1/BRM degrader AU15330 on protein expressions in MLL1-rearranged AML cells
2025-04-28 | PXD055994 | Pride
Proteomics Effect of CDK7 inhibitor, FHD-286, SNDX-50469, or Tasquinimod on protein expression alterations in patient-derived secondary AML or de novo MLL1-rearranged AML cells
2025-04-28 | PXD053548 | Pride
Transcriptomics Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML [RNA-seq]
2026-01-21 | GSE297480 | GEO
Genomics Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML [ATAC-seq]
2026-01-21 | GSE297475 | GEO
Genomics Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML [ChIP-Seq]
2026-01-21 | GSE297477 | GEO
Genomics BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (scATAC-Seq)
2024-03-01 | GSE252936 | GEO
Transcriptomics BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (scRNA-Seq)
2024-03-01 | GSE252937 | GEO